AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20727177 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgrouping for targeted treatment system (multi-component quality improvement intervention including educational courses, outreach visits, audit/feedback, mentoring, and organisational support)
Number of subjects: 1000
Study 20727177 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgrouping for targeted treatment system
Number of subjects: 1000
Study 16938152 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight lightwand
Number of subjects: 64
Study 16938152 — intervention group
Group type: COMPARATOR
Intervention: Eschmann multiple-use introducer
Number of subjects: 64
Study 16116132 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injections
Number of subjects: 12
Study 16116132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11969277 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg intravenous bolus, then 40 mg subcutaneously every 8 h)
Number of subjects: 300
Study 11969277 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 U intravenous bolus, then 30,000 U 24 h(‐1), adjusted to an activated partial thromboplastin time 2‐2.5x normal)
Number of subjects: 300
Study 11969277 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 300
Study 11969277 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 300
Study 10817084 — intervention group
Group type: EXPERIMENTAL
Intervention: C. pneumoniae immunoglobulin G levels
Number of subjects: 704
Study 10817084 — intervention group
Group type: EXPERIMENTAL
Intervention: cytomegalovirus immunoglobulin G levels
Number of subjects: 704
Study 7911820 — intervention group
Group type: COMPARATOR
Intervention: non-triglyceride-fraction from coffee oil (0.75 g/d for 4 weeks)
Number of subjects: 15
Study 7911820 — intervention group
Group type: COMPARATOR
Intervention: purified cafestol (73 mg/d) plus kahweol (58 mg/d)
Number of subjects: 15
Study 7911820 — intervention group
Group type: COMPARATOR
Intervention: Oil from Robusta beans (contains cafestol)
Number of subjects: 15
Study 7911820 — intervention group
Group type: EXPERIMENTAL
Intervention: coffee oils and brews containing cafestol
Number of subjects: 15
Study 2756913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy supplement
Number of subjects: 108
Study 2756913 — intervention group
Group type: COMPARATOR
Intervention: Low-energy supplement
Number of subjects: 108
Study 5320587 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment with griseofulvin
Number of subjects: 395
Study 5320587 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment with griseofulvin
Number of subjects: 395
Study 31637971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment arm
Number of subjects: 8913
Study 31637971 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment arm
Number of subjects: 8913
Study 31637971 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline albuminuria (≥30 mg/g) versus not
Number of subjects: 8913
Study 29911802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine nasal spray
Number of subjects: 20
Study 26472518 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible group for omitting ALND according to Z0011 criteria
Number of subjects: 658
Study 26472518 — intervention group
Group type: COMPARATOR
Intervention: Ineligible group for omitting ALND according to Z0011 criteria
Number of subjects: 658
Study 22906039 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC
Number of subjects: 40
Study 22906039 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 40
Study 22906039 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite
Number of subjects: 40
Study 22906039 — intervention group
Group type: COMPARATOR
Intervention: Control (sound teeth)
Number of subjects: 40
Study 20729010 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI) - single face-to-face session
Number of subjects: 418
Study 20729010 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 418
Study 19104900 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin inguinal incision carried out 3-4 cm above the inguinal ligament (group A)
Number of subjects: 62
Study 19104900 — intervention group
Group type: COMPARATOR
Intervention: Skin inguinal incision carried out below the inguinal ligament (group B)
Number of subjects: 62
Study 16713936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics with enhanced patient tracking efforts
Number of subjects: 2190
Study 16713936 — intervention group
Group type: COMPARATOR
Intervention: Control clinics with standard documentation
Number of subjects: 2190
Study 16713936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention branch (inactive infants removed)
Number of subjects: 2190
Study 16713936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention branch (inactive infants included)
Number of subjects: 2190
Study 12457078 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 28 days followed by 10 mg/day)
Number of subjects: 286
Study 12457078 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 286
Study 12457078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 10749249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal analysis of nuclear medicine images
Number of subjects: 28
Study 9028719 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexican Americans
Number of subjects: 1276
Study 9028719 — intervention group
Group type: COMPARATOR
Intervention: non-Hispanic whites
Number of subjects: 1276
Study 1587633 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 15
Study 3710634 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solution (1.0 g)
Number of subjects: 6
Study 3710634 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly dissolving tablet (1.0 g)
Number of subjects: 6
Study 3710634 — intervention group
Group type: COMPARATOR
Intervention: Sustained release product C (1.0 g)
Number of subjects: 6
Study 3710634 — intervention group
Group type: COMPARATOR
Intervention: Sustained release product D (1.0 g)
Number of subjects: 6
Study 3710634 — intervention group
Group type: COMPARATOR
Intervention: Sustained release product E (1.0 g)
Number of subjects: 6
Study 29457540 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ mononuclear cell therapy (CD34+MCT)
Number of subjects: 479
Study 29457540 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD34+ cell dosage
Number of subjects: 479
Study 26936844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mission Possible: Parents and Kids Who Listen
Number of subjects: 127
Study 26936844 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 127
Study 25274192 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate or calcium carbonate (1 g/d)
Number of subjects: 100
Study 25274192 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline hydroxyapatite (MCH)
Number of subjects: 100
Study 21941017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 15°C for 5 minutes after training
Number of subjects: 8
Study 20233534 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered manual oesophagogastric anastomosis
Number of subjects: 516
Study 20233534 — intervention group
Group type: COMPARATOR
Intervention: Stapler oesophagogastric anastomosis
Number of subjects: 516
Study 18817961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg) plus Tamsulosin (0.4 mg)
Number of subjects: 0
Study 18817961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0
Study 18817961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER (4 mg)
Number of subjects: 0
Study 18817961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER plus Tamsulosin
Number of subjects: 0
Study 18817961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16053954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HF) at 200 ml/kg/h over 8 hours
Number of subjects: 61
Study 16053954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration combined with mild hypothermia (HF+HT) at 32 degrees C for 24 hours
Number of subjects: 61
Study 16053954 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard supportive care)
Number of subjects: 61
Study 12449206 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 20)
Number of subjects: 40
Study 12449206 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 10498147 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiography in the occluded IRA group (n = 35)
Number of subjects: 89
Study 10498147 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered QRS duration in the occluded IRA group (n = 35)
Number of subjects: 89
Study 10498147 — intervention group
Group type: EXPERIMENTAL
Intervention: V40 in the occluded IRA group (n = 35)
Number of subjects: 89
Study 10498147 — intervention group
Group type: COMPARATOR
Intervention: Patent IRA group (n = 54)
Number of subjects: 89
Study 8709353 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pigtail ureteral stent
Number of subjects: 194
Study 8709353 — intervention group
Group type: COMPARATOR
Intervention: No stent
Number of subjects: 194
Study 1929823 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate (100 micrograms injected subcutaneously)
Number of subjects: 9
Study 1929823 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 9
Study 1929823 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate
Number of subjects: 9
Study 6797863 — intervention group
Group type: COMPARATOR
Intervention: Group 1: 40.3 ± 2.0 kcal.kg‐1.day‐1 (7.0 mg glucose.kg‐1.min‐1) and 0.27 ± 0.02 g N.kg‐1.day‐1
Number of subjects: 30
Study 6797863 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 53.4 ± 6.8 kcal.kg‐1.day‐1 (9.2 mg glucose.kg‐1.min‐1) and 0.36 ± 0.05 g N.kg‐1.day‐1
Number of subjects: 30
Study 30880321 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg three times a day for 30 days
Number of subjects: 30
Study 30880321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CoQ10)
Number of subjects: 30
Study 29275370 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable Hypertension Control (PHC) therapy activated after baseline measurements
Number of subjects: 27
Study 29275370 — intervention group
Group type: COMPARATOR
Intervention: Conventional pacing during the Run-In period
Number of subjects: 27
Study 26672997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten‐week home‐based intervention according to the Dutch guidelines for occupational therapy in Parkinson's disease
Number of subjects: 124
Study 24974307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy skills training (DBT‐ST)
Number of subjects: 44
Study 24974307 — intervention group
Group type: COMPARATOR
Intervention: Activities-based support group (ASG)
Number of subjects: 44
Study 21208581 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 30
Study 21208581 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study 19273785 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal/grid photocoagulation
Number of subjects: 306
Study 19273785 — intervention group
Group type: COMPARATOR
Intervention: 1 mg intravitreal triamcinolone
Number of subjects: 306
Study 19273785 — intervention group
Group type: COMPARATOR
Intervention: 4 mg intravitreal triamcinolone
Number of subjects: 306
Study 17905097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin A (BTX‐A) injections (100 U or 200 U) followed by cystoscopic hydrodistension
Number of subjects: 19
Study 17905097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin A (BTX‐A) injections
Number of subjects: 19
Study 14971982 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined weights and plyometrics training (2 sessions per week for 8 weeks)
Number of subjects: 11
Study 14971982 — intervention group
Group type: COMPARATOR
Intervention: Normal training (Control group, n = 5)
Number of subjects: 11
Study 11887833 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled clinical trials (RCCTs)
Number of subjects: 0
Study 11887833 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 0
Study 11887833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective observational data
Number of subjects: 0
Study 9205915 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐PTFE membrane
Number of subjects: 18
Study 9205915 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐PTFE + HAC
Number of subjects: 18
Study 9205915 — intervention group
Group type: COMPARATOR
Intervention: HAC alone
Number of subjects: 18
Study 9205915 — intervention group
Group type: COMPARATOR
Intervention: CF
Number of subjects: 18
Study 8288779 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% gold(tri)chloride
Number of subjects: 200
Study 8288779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% gold(tri)chloride
Number of subjects: 200
Study 8288779 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold replacement in dentures
Number of subjects: 200
Study 3675745 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% lactose (LAC)
Number of subjects: 12
Study 3675745 — intervention group
Group type: COMPARATOR
Intervention: 50% lactose: 50% glucose polymer (LAC + GP)
Number of subjects: 12
Study 31554519 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary quality of life intervention
Number of subjects: 117
Study 31554519 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 117
Study 29141255 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (ESC) 10-30 mg (mean dose 15.2, SD±9.2)
Number of subjects: 60
Study 29141255 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (NOR) 50-150 mg (mean dose 106.2, SD±8.2)
Number of subjects: 60
Study 29141255 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (VEN) 75-225 mg (mean dose 181.3, SD±8.8)
Number of subjects: 60
Study 26467385 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard categorical system for assessing toxicity
Number of subjects: 0
Study 26467385 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary system ('related' vs. 'unrelated')
Number of subjects: 0
Study 26467385 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability estimation
Number of subjects: 0
Study 23944720 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg QD plus PegIFN/RBV
Number of subjects: 12
Study 23944720 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD plus PegIFN/RBV
Number of subjects: 12
Study 23944720 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus PegIFN/RBV
Number of subjects: 12
Study 23944720 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD plus PegIFN/RBV (treatment-experienced)
Number of subjects: 12
Study 22357699 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD (eGFR < 60 mL/min)
Number of subjects: 11140
Study 22357699 — intervention group
Group type: COMPARATOR
Intervention: No CKD (eGFR ≥ 60 mL/min)
Number of subjects: 11140
Study 20555279 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 30
Study 20555279 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study 17911482 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 40
Study 17911482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16208143 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (nutritional doses)
Number of subjects: 5086
Study 16208143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5086
Study 16208143 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 5086
Study 16208143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and trace elements
Number of subjects: 5086
Study 11974515 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular visits from volunteers for ten weeks
Number of subjects: 40
Study 11974515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visits)
Number of subjects: 40
Study 9923780 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitually sun‐exposed body sites
Number of subjects: 506
Study 9923780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently exposed skin of the trunk
Number of subjects: 506
Study 9923780 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 506
Study 9923780 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 506
Study 9923780 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body and site‐specific MN counts and densities
Number of subjects: 506
Study 7577191 — intervention group
Group type: EXPERIMENTAL
Intervention: IOTN Learning Package in the form of a poster
Number of subjects: 57
Study 7577191 — intervention group
Group type: EXPERIMENTAL
Intervention: IOTN Learning Package in the form of a booklet
Number of subjects: 57
Study 7577191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Learning Package)
Number of subjects: 57
Study 1691921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg m‐2 on days 1 and 29 and vindesine 3 mg m‐2 weekly x 6
Number of subjects: 201
Study 1691921 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 201
Study 1691921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg m‐2 on days 1 and 29 and vindesine 3 mg m‐2 weekly x 6 (for patients without dissemination)
Number of subjects: 201
Study 1691921 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (for patients without dissemination)
Number of subjects: 201
Study 376042 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 27
Study 376042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 376042 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 27
Study 31588574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime static ankle-foot orthoses (AFOs)
Number of subjects: 187
Study 31588574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime dynamic ankle-foot orthoses (AFOs)
Number of subjects: 187
Study 31588574 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime static ankle-foot orthoses (AFOs)
Number of subjects: 187
Study 29212415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation intervention group
Number of subjects: 44
Study 29212415 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 44
Study 28232854 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella 2.5
Number of subjects: 18
Study 25548122 — intervention group
Group type: EXPERIMENTAL
Intervention: matrix‐induced autologous mesenchymal stem cell implantation (m‐AMI)
Number of subjects: 14
Study 25548122 — intervention group
Group type: COMPARATOR
Intervention: matrix‐induced autologous chondrocyte implantation (m‐ACI)
Number of subjects: 14
Study 23216998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone (40 mg/day, with food)
Number of subjects: 869
Study 23216998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 869
Study 23216998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 869
Study 21292249 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary rewards for uninteresting questions
Number of subjects: 0
Study 21292249 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary rewards for interesting questions
Number of subjects: 0
Study 21292249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no monetary rewards) for uninteresting questions
Number of subjects: 0
Study 21292249 — intervention group
Group type: COMPARATOR
Intervention: Control group (no monetary rewards) for interesting questions
Number of subjects: 0
Study 19432567 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement (60 mg daily)
Number of subjects: 1164
Study 19432567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1164
Study 15742225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 846
Study 11840040 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha + Ribavirin (3 million U/m2 subcutaneous interferon-alpha three times weekly and 15 mg/kg oral ribavirin daily for 12 months)
Number of subjects: 22
Study 11840040 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (3 million U/m2 subcutaneous interferon-alpha three times weekly for 12 months)
Number of subjects: 22
Study 11840040 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha + Ribavirin
Number of subjects: 22
Study 11840040 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 22
Study 10520732 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amisulpride once daily for 4 days
Number of subjects: 12
Study 10520732 — intervention group
Group type: COMPARATOR
Intervention: Caffeine slow release (600 mg)
Number of subjects: 12
Study 8821610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemether at a total dose of 700 mg (300 mg initially, followed by 100 mg daily for 4 days)
Number of subjects: 109
Study 8821610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen of artemether-mefloquine (300 mg oral artemether initially, followed by 750 mg oral mefloquine after 24 h)
Number of subjects: 109
Study 2254352 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 126
Study 2254352 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 126
Study 7217025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular molindone
Number of subjects: 0
Study 7217025 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 0